U.S. Food & Drug Administration on Nov. 6 said it will ban an ingredient common in many over-the-counter cold/cough medicines and diet products, forcing marketers to reformulate their products and adjust marketing. The FDA swiftly followed the lead of one of its advisory panels, which on Oct. 19 voted to ban the substance known as PPA because of research showing it can lead to stroke. Brands affected include American Home Products Corp.'s Dimetapp, Novartis Consumer Health's Triaminic and Thompson Medical Co.'s Dexatrim. The FDA's move could be a huge blow to marketers just as the heavy-use season unfolds. It was unclear whether the ruling would prompt a mass recall or simply mean future product would be altered.
Copyright November 2000, Crain Communications Inc.